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The British public are offered alternating periods of lockdown and relaxation of restrictions, 
with increasing economic and social damage1. Each relaxation will almost certainly trigger a 
further epidemic wave of deaths. These cycles will kill tens and perhaps hundreds of 
thousands of people before a vaccine becomes available, and the most disadvantaged are 
already suffering the most.  
 
There is an alternative: universal repeated testing2. We recommend evaluation of weekly 
Covid-19 antigen testing of the whole population in an entire city as a demonstration site 
(preferably several towns and cities), with strict household quarantine following a positive 
test. Quarantine ends when all residents test negative at the same time. Everyone else can 
resume normal life if they choose to. This should be assessed for feasibility in one or more 
cities with populations of 200,000-300,000. Such a feasibility study should begin as soon as 
possible and continue after the current lockdown ends, when the infection rate will be fairly 
low but rising. The rate at which it then rises or falls compared with the rest of the UK will 
be apparent within a few weeks. A decision can then be taken on national roll-out, 
beginning in high-risk areas and limited only by reagent supplies. If this works hundreds of 
thousands of people living in the UK may be saved, not to mention intensive care overload 
and the miseries of unemployment, mental ill health and other adverse outcomes of 
lockdown.  
 
A local population of 200,000 with 90% compliance will require 26,000 tests per day, plus a 
small excess to offer daily antigen testing for NHS staff and care workers. Such a study is 
likely to have the enthusiastic support of the population. Whatever the results these data 
will enable policy to be based on real-time evidence (instead of modelling assumptions) on 
new infection rates in the expanding regularly tested population and the untested 
remainder. The latter can be monitored by testing population samples as well as by NHS 
number linkage to hospital diagnoses and GP records. Complementary strategies including 
contact tracing and phone apps will be critical in the unscreened population, and may 
enable testing to be done less frequently as prevalence falls. Testing would be voluntary, 
but penalties for breaching quarantine following a positive test in a household could be 
considered. Helplines would be provided to support quarantined households with access to 
income compensation, mental health support and food delivery.  
 
National roll-out will entail mobilisation of community assets. Public advisory groups and 
citizens supporting these efforts will be indispensable.  A voluntary “Dunkirk spirit” is the 
only way for 10 million tests to be done daily by collaborating university and commercial 
labs with the necessary quality-checked equipment (a PCR machine). PCR reagents should 
be obtained from chemical manufacturers rather than clinical test companies and exempt 
from regulatory requirements on medical testing to limit costs and ensure supplies. This 
may require emergency legislation.  
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Open letter to UK Government sent April 10 2020 
Stopping the lockdown and ending the 
epidemic by universal weekly testing as 
the exit strategy 
Dear Mr Dominic Raab, Sir Keir Starmer, Mr Jeremy Hunt, Mr Matt Hancock, Mr Jonathan 
Ashworth, Professors Sir Patrick Vallance, Chris Whitty and John Newton, 
 
 
The British public have so far been offered the strategy of alternating periods of lockdown and 
relaxation of restrictions. However, extended periods of lockdown will increase economic and 
social damage, and periods of relaxation of restrictions are almost certainly going to trigger 
further epidemic waves of fatalities. We strongly support expanding testing as quickly as 
possible, building up local public health teams to get our systems in place for case detection 
and contact tracing. We note however that asymptomatic and pre-symptomatic transmission 
may be a major factor in the epidemic. The resurgence can be slowed by contact tracing, 
behavioural changes and various degrees of physical distancing but it cannot be stopped. 
These cycles will kill tens and perhaps hundreds of thousands of people before a vaccine 
becomes available, and the most disadvantaged will suffer most.  
 
As experienced public health researchers and practitioners we believe there is an alternative 
strategy that can restore normal life and economic recovery: universal repeated testing. We 
strongly recommend evaluation of weekly Covid-19 antigen testing of the whole population in 
an entire city as a demonstration site (preferably several towns and cities if funding is 
available), with strict household quarantine following a positive test. Visitors are allowed but 
are quarantined on arrival. Quarantine ends when all residents test negative at the same time. 
Lockdown will end immediately for everyone else, although some may choose to remain 
isolated. This should be assessed for feasibility in one or more cities with populations of 
~200,000. Ending lockdown with weekly testing is likely to suppress viral transmission while 
restoring normal life. Such a feasibility study could begin immediately with Government 
support. The study will have begun after lockdown so the initial infection rate wi ll be fairly low. 
The rate at which it then rises or falls will be apparent within a few weeks. A decision can then 
be taken on national roll-out, beginning in high-risk areas and limited only by reagent supplies. 
If this works hundreds of thousands of lives of people living in the UK may be saved, not to 
mention NHS intensive care overload and the miseries of lockdown and unemployment.  
 
The site(s) should be selected in consultation with local health and administrative authorities. 
Public awareness and implementation will be organised by a community advisory committee 
led by local public health specialists and PHE consultants in communicable disease control. 
To establish the feasibility of national roll-out all tests will be performed by staff in local 
academic or commercial labs with PCR machines currently used for other purposes. A city of 
200,000 with 90% compliance will require 26,000 tests per day, plus a small increase to offer 
daily antigen testing for NHS staff and care workers. Such a study can be done without 
encroachments on privacy rights and with the consent of the population. Other requirements 
for the feasibility study are a population register of the city, self-sample kits and a system for 
delivering and collecting samples (see below).  
 
Whatever the results these data will enable policy to be based on real-time evidence (instead 
of modelling assumptions) on new infection rates in the expanding regularly tested population 
and the untested remainder. The latter can be monitored by testing population samples as 
well as by NHS number linkage to hospital diagnoses and GP records. Complementary and 
alternative strategies including contact tracing and mobile phone apps will be particularly 
important in the unscreened population, and may enable testing to be done less frequently as 
prevalence falls. Local public health staff supported by volunteers will assist in developing, 
implementing and evaluating these as well as supporting public information, home visits and 
helplines. To minimise disruption, access to the city would be unrestricted with occasional 
testing of incomers at temporary checkpoints. Testing would be voluntary, but imposing 
penalties for breaching quarantine following a positive test in a household could be 
considered. Helplines would be provided for quarantined households for exemption requests, 




If the epidemic is controlled without lockdown in the feasibility study, public pressure for 
national roll-out will be irresistible. A ballpark cost-benefit analysis shows a total cost per year 
following national roll-out of £14 billion, the most speculative components being £100 million 
to expand facilities for manufacturing reagents and £2 per test for PCR reagents (£7 billion 
per year for 10 million tests per day). This is a small fraction of the economic costs of 
lockdown. Chemical manufacturers rather than clinical test companies must be involved to 
limit costs and ensure supplies. Quality control can be minimal because PCR is sensitive and 
any false negatives tend to be the least infectious cases, and because both false negatives 
and false positives will be retested a week later. 
Universal repeat testing has been dismissed as impractical because so many tests are 
required and because it has never been tried. Each of the imagined obstacles is simply a 
shortage that can be met, perhaps quite quickly, by (preferably British) manufacturers.  
 
The facilities needed are: 
1. A register of names, dates of birth and addresses of all residents registered with a GP, to 
be updated as necessary with test results, changes of address and addition of unregistered 
subjects. Anonymous registration with local outlets for sample collection and delivery is 
needed for those reluctant to give name and address. 
2. The equivalent of 14,000 96-well PCR machines running night and day. Enough machines 
and experienced staff to operate them are already in place in large and small academic and 
commercial labs throughout the UK, including possible demonstration sites. Posts for three 8-
hour shifts might be needed. 
3. Self-sample swabs, sample transport tubes individually labelled with name, date of birth 
and barcoded ID, PCR reagents and microtiter plates for 10 million tests per day. Additional 
production facilities must be commissioned if necessary. 
4. Arrangements to deliver and collect samples from every household once a week, with 
delivery to a testing lab within a few hours. Results would be entered online by the lab within a 
day of sample collection. Positive results in those without phone or email would be delivered 
by courier. 
 
This high throughput would depend on various regulatory emergency waivers: 
1. Lab staff would wear PPE where necessary but would not be accredited to conduct medical 
tests. 
2. Laboratories would be advised on precautions but not accredited for handling infectious 
samples. 
3. PCR reagent production with normal non-medical quality control cannot be hampered by 
patents or regulations on medical test manufacture.  
 
The idea of conducting regular population-wide mass testing, which has never been tried in a 
large country, is unusual in two respects. First, a voluntary “Dunkirk spirit” collaboration of all 
university and commercial labs that already have the necessary equipment (a PCR machine) 
is the only way for 10 million tests to be done daily. Second, manufacture and testing would 
be arranged in consultation with chemical manufacturers rather than clinical test companies 
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